@article{0dd285c94cba4033afd94a34e8cb629b,
title = "Comparison of Short-Wavelength Reduced-Illuminance and Conventional Autofluorescence Imaging in Stargardt Macular Dystrophy",
abstract = "Purpose To compare grading results between short-wavelength reduced-illuminance and conventional autofluorescence imaging in Stargardt macular dystrophy. Design Reliability study. Methods SETTING: Moorfields Eye Hospital, London (United Kingdom). PATIENTS: Eighteen patients (18 eyes) with Stargardt macular dystrophy. OBSERVATION PROCEDURES: A series of 3 fundus autofluorescence images using 3 different acquisition parameters on a custom-patched device were obtained: (1) 25% laser power and total sensitivity 87; (2) 25% laser power and freely adjusted sensitivity; and (3) 100% laser power and freely adjusted total sensitivity (conventional). The total area of 2 hypoautofluorescent lesion types (definitely decreased autofluorescence and poorly demarcated questionably decreased autofluorescence) was measured. MAIN OUTCOME MEASURES: Agreement in grading between the 3 imaging methods was assessed by kappa coefficients (κ) and intraclass correlation coefficients. Results The mean ± standard deviation area for images acquired with 25% laser power and freely adjusted total sensitivity was 2.04 ± 1.87 mm2 for definitely decreased autofluorescence (n = 15) and 1.86 ± 2.14 mm2 for poorly demarcated questionably decreased autofluorescence (n = 12). The intraclass correlation coefficient (95% confidence interval) was 0.964 (0.929, 0.999) for definitely decreased autofluorescence and 0.268 (0.000, 0.730) for poorly demarcated questionably decreased autofluorescence. Conclusions Short-wavelength reduced-illuminance and conventional fundus autofluorescence imaging showed good concordance in assessing areas of definitely decreased autofluorescence. However, there was significantly higher variability between imaging modalities for assessing areas of poorly demarcated questionably decreased autofluorescence.",
author = "Strauss, {Rupert W.} and Beatriz Munoz and Anamika Jha and Alexander Ho and Cideciyan, {Artur V.} and Kasilian, {Melissa L.} and Yulia Wolfson and Sadda, {Srini Vas} and Sheila West and Hendrik Scholl and Michel Michaelides",
note = "Funding Information: Funding/Support: The ProgStar studies are supported by the Foundation Fighting Blindness Clinical Research Institute (FFB CRI) and a grant to FFB CRI by the U.S. Department of Defense USAMRMC TATRC , Fort Meade, Maryland (grant numbers W81-XWH-07-1-0720 and W81XWH-09-2-0189 ). Dr Hendrik P.N. Scholl is supported by the Shulsky Foundation , New York, NY; Ocular Albinism Research Fund (Clark Enterprises Inc) ; unrestricted grant to the Wilmer Eye Institute from Research to Prevent Blindness ; and Baylor-Johns Hopkins Center for Mendelian Genetics (National Human Genome Research Institute, NHGRI/NIH ; identification number: 1U54HG006542-01 ). He is the Dr Frieda Derdeyn Bambas Professor of Ophthalmology. Dr Rupert Strauss is supported by the Austrian Science Fund (FWF; project number: J 3383-B23 ) and the Foundation Fighting Blindness Clinical Research Institute (USA) . Dr Michel Michaelides is supported by grants from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust and UCL Institute of Ophthalmology , Fight For Sight (UK), The Macular Society (UK), Moorfields Eye Hospital Special Trustees , and Moorfields Eye Charity ; by a multiuser equipment grant from The Wellcome Trust [ 099173/Z/12/Z ]; and by the Foundation Fighting Blindness (USA) and Retinitis Pigmentosa Fighting Blindness . Dr Michaelides is a recipient of an FFB Career Development Award . The funding organizations had no role in the design or conduct of this research, nor in the preparation of this article. Financial disclosures: Hendrik P.N. Scholl is a paid consultant of the following entities (not including the National Institutes of Health): Shire; Ocata Therapeutics, Inc; Guidepoint Global, LLC; Gerson Lehrman Group; DeMatteo Monness Consulting. Dr Scholl is member of the Scientific Advisory Board of Vision Medicines, Inc and of the Clinical Advisory Board of Gensight Biologics; is member of the Data Monitoring and Safety Board/Committee of the following entities (not including the National Institutes of Health): Genentech Inc/F. Hoffmann-La Roche Ltd; Genzyme Corp/Sanofi, and ReNeuron Group Plc/Ora Inc; and serves as a member of the Ophthalmic Devices Panel of the Medical Devices Advisory Committee, Food and Drug Administration (FDA), Silver Spring, Maryland, United States. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. Johns Hopkins University and Bayer Pharma AG have an active research collaboration and option agreement. Hendrik P.N. Scholl is principal investigator of grants at The Johns Hopkins University sponsored by the following entities (not including the National Institutes of Health): QLT, Inc and NightstaRx Ltd. Grants to investigators at Johns Hopkins University are negotiated and administered by the institution (such as the School of Medicine) that receives the grants, typically through the Office of Research and Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s). SriniVas Sadda receives support from Optos (Marlborough, MA); Carl Zeiss Meditec (Jena, Germany); Nidek (Padova, Italy); Topcon Medical Systems (Oakland, NJ). The following authors have no financial disclosures: Rupert W. Strauss, Beatriz Mu{\~n}oz, Anamika Jha, Alexander Ho, Artur V. Cideciyan, Melissa L. Kasilian, Yulia Wolfson, Sheila West, and Michel Michaelides. All authors attest that they meet the current ICMJE criteria for authorship. Publisher Copyright: {\textcopyright} 2016 The Authors",
year = "2016",
month = aug,
day = "1",
doi = "10.1016/j.ajo.2016.06.003",
language = "English (US)",
volume = "168",
pages = "269--278",
journal = "American journal of ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
}